PreveCeutical Medical Inc.

account_balanceLife Sciences

  About Us
Headquartered in Vancouver, British Columbia, PreveCeutical Medical Inc. has a world class team with a passion for researching and developing innovative solutions for unmet clinical needs. Bringing to market treatments and therapies that make real, palpable differences in the lives of those who need them. The company is staking out important positions in diverse areas such as diabetes and obesity, pain management, neurological disorders and cancer.
Website

https://www.preveceutical.com

https://www.preveceutical.com

Headquarters

1177 West Hastings Street, Suite 2200 Vancouver, British Columbia V6E 2K3

Public Issuance

2014

Shares Outstanding

390.19m

Corporate Filings

SEDAR

Stock Symbol

PREV:CNX

location_on1177 West Hastings Street, Suite 2200 Vancouver, British Columbia V6E 2K3
 3 Reasons to invest
  1. Facing scarce resources, policymakers must determine how best to invest in their country’s future. Investment in health can save costs and facilitate economic growth by increasing productivity.  Economic analyses help governments and international donors identify health practices that are not only feasible, but also the best value for money.

  2. The exact global cost of cancer is unknown, but it is undoubtedly well into the hundreds of billions of dollars per year. In the United States alone, the estimated cost of cancer in 2009, including direct medical costs as well as the cost of lost productivity due to premature death, was US$216.6 billion per year.  The global cost of cancer is expected to increase due to increases in the number of new cancer cases as well as the growing cost of cancer therapies.

  3. A substantial part of this cost can be averted by investing in cancer prevention, early detection, and treatment. For example, cost-effective strategies to address common cancer risk factors such as tobacco use, alcohol abuse, unhealthy diet and physical inactivity in low- and middle-income countries would cost only US$2 billion per year, a small amount compared to the costs incurred by the total disease burden. For example, in developing countries, cervical cancer screenings that require little laboratory infrastructure, such as simple visual inspection of the cervix with acetic acid or DNA testing for HPV in cervical cell samples, cost less than US$500 per year of life saved. In general, cancer prevention is far more cost-effective than treatment.

If you are interested in investing in us, please join management, shareholders and other interested investors in our Investor Group. We want to ensure all investors are well informed and have access to important investor information.

Join Investor Group

+ Add Member
 Current Team
Thumb preveceutical image sol gel
X
Sol-Gel Delivery Platform for Nose-to-Brain Delivery of Therapeutic Compounds



Developing the first, sustained-release, CBD-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. Our proprietary nasal formulations will also be designed to be universally-patient friendly, meaning formulations that can be used in children and adults alike.

Sol-gels are taken via nasal administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This effectively bypasses the stomach and intestines - eliminating first pass metabolism - and may dramatically improve bioavailability - even compared to nasal sprays and other newer delivery systems. Additionally, the gel stays in the nasal passages, slowly releasing the CBD while keeping it active for up to seven days. The ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.

add
Thumb preveceutical image scorpion venom
X
Nature Identical Peptides from the Caribbean Blue Scorpion Venom to Assist with Cancer-Targeted Treatment

We plan to identify active peptides that are providing the immune boosting, pain relieving, and tumour selective properties, then test what happens when used on various abnormal cells like brain, lung and breast cancers.

A preclinical research and development program is now underway.   It was designed and is being directed by our Chief Science Officer, Dr. Mak Jawadekar, PhD.

PreveCeutical, and partner Uniquest, are currently screening peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where there exists unmet clinical need, such as cancer. There are numerous research papers in the public domain which show the anecdotal findings and efficacy of venom peptides taken through the proven route of administration on cancerous cells/tumours. Our initial focus will be on targeting a very aggressive form of brain cancer (glioma). From there we plan to extend the program to screen our library of nature identical peptides in a high throughput screening (HTS) manner across a range of other cancers.
add
Thumb preveceutical image2
X
Engineering Peptide Therapeutics for Non-Addictive Analgesia

PreveCeutical Medical Inc., and partner UniQuest Pty Ltd have signed a research and option agreement proposing to expand the use of their disulphide linker technology to develop non-addictive analgesics for moderate-to-severe pain.

This Research and Development program, led by Dr. Harry Parekh in-conjunction with his fellow collaborators at The University of Queensland’s School of Pharmacy, involves peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment and efficacy determinations in appropriate animal models of pain and inflammation, and may encompass either party’s intellectual property and product line and other pharmaceutical offerings that may fall within the peptide Research and Development program.

Dr. Parekh commented “This is a very exciting and important program as we focus on engineering a novel class of drugs derived from our very own endogenous pain pathways, for example when pain and inflammatory insults occur. Our preliminary work has highlighted that by using our proprietary linker technology we can enhance stability while maintaining, and in some cases enhancing the potency of lead bioactives. Having PreveCeutical on board will accelerate our current program, allowing us to rapidly expand and screen the bioactive library, taking the most promising candidates through to efficacy and pharmacokinetic evaluation.

Peptides are currently being used to target an array of disease indications including metabolic disorders, pain, cancers, cardiovascular and infectious diseases.  The therapeutic peptide market is projected to undergo considerable expansion in the foreseeable future as technologies to enhance their stability and bioavailability emerge.
add
Thumb preveceutical obesity
X
Dual Gene Therapy Targeting Type 2 Diabetes and Obesity

PreveCeutical’s advantage is demonstrated proof of concept. Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in type 2 diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.

“With diabetes, over-production of a particular protein molecule has been identified and purposed to be responsible for the key drivers of diabetes and obesity, starting patient on an inevitable journey of significant co-morbidity and increased rates of mortality.

PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels; this would in turn help our cells to absorb glucose, thus reducing blood sugar levels and prevent the body from storing excessive fat from our diet. Thus gene-silencing does not represent a mere management for diabetes and obesity, it represents the potential for a bona fide cure or, in cases where patients have a pre-disposition to diabetes or are in the pre-diabetes state, it can be applied as a ‘PreveCeutical’ to halt progress to the full-blown disease.

This is not merely theoretical. Five years of painstaking work has gone into this initiative and management has already taken this research through the proof-of-concept stage in cellular models of diabetes and obesity.” – Chief Research Officer: Dr. Harry Parekh, PhD, MRPharmS
add
Company offering default img
X
Offering Title

Offering Description

add
+ Add Publication
  Publications

Add Publication Title

Add Publication Description

+ Add Video
  Media
X

Add Video Title

Add Video Description

X

Add Video Title

Add Video Description

X

Add Video Title

Add Video Description

X

Add Video Title

Add Video Description

X

Add Video Title

Add Video Description

X

Add Video Title

Add Video Description

chevron_leftchevron_right